

Press release

October 29, 2018

NeoDynamics AB (publ) publishes prospectus and enters agreement on additional subscription commitment

NeoDynamics AB (publ) ("NeoDynamics") – with a new patented micropulse technology to simplify and improve the precision in biopsy procedures – today publishes a prospectus for the upcoming issue of units, in which the subscription period starts on the 31st of October, 2018. The prospectus is available on the websites of the NeoDynamics (www.neodynamics.com) and Sedermera Fondkommission (www.sedermera.se). The prospectus is also available at www.spotlightstockmarket.com. Teaser and subscription form will be published on the webpages above at the start of the subscription period. Furthermore, NeoDynamics hereby announces that an additional party, Gryningskust Holding AB, has given a subscription commitment of SEK 1 999 980,00, of which SEK 999 990,00 constitutes bridge finance. The total commitments in the issue of units is therefore approximately SEK 37 million, of which subscription commitments amounts to SEK 31 million (of which approximately SEK 15.5 million constitutes bridge finance) and SEK 6 million is a free top-down guarantee subscription from the company's principal shareholder. NeoDynamics has thus beforehand agreed on a total of 73 percent of the initial issue of units through subscription commitments and free top-down guarantee subscription. Before the additional subscription commitment, the equivalent number was 69 percent.

Financial advisor

Sedermera Fondkommission is the financial advisor and Issuing Agent to NeoDynamics in connection with the issue of units and the planned listing on Spotlight. Nordnet Bank AB is acting as Selling Agent in the issue of units.

For further information about the upcoming IPO and the planned listing, please contact:

Sedermera Fondkommission
Telephone: +46 (0) 40-615 14 10
E-mail: info@sedermerna.se

For further information about NeoDynamics, please contact:

Anna Eriksrud, CEO NeoDynamics AB (publ)
Telephone: +46 8 522 79 667
E-mail: anna.eriksrud@neodynamics.se

This information is information that NeoDynamics AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication by the contact person above on October 29, 2018.

About NeoDynamics

Every year, approximately 2.1 million women worldwide are diagnosed with breast cancer, increasing by five percent per year. NeoDynamics has developed the NeoNavia® biopsy system which facilitates and improves tissue sampling (biopsies) in breast cancer patients, with a new patented micropulse technology. This method gives better precision and better control. In close collaboration with leading clinicians, we have gained experience of having used the technology in more than 300 procedures at around 15 university hospitals across Europe. NeoDynamics is currently completing development of the commercial version of NeoNavia. Among several design and usability features it integrates micropulse technology with multiple needle options for maximum versatility. NeoNavia is expected to be launched towards the end of 2019 in a breast biopsy market worth approximately USD 500 million per year. The technology is likewise suited for cancer diagnostics in other organs such as prostate, lung, kidney and liver.